Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy

Sato, Ken; Yamazaki, Yuichi; Kanayama, Yuki; Uehara, Daisuke; Tojima, Hiroki; Suga, Takayoshi; Kakizaki, Satoru; Sohara, Naondo; Horiguchi, Norio; Uraoka, Toshio

doi:10.1002/ccr3.5690

Cited by 1 publication

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No SAE or early discontinuation of therapy were observed. After DAA therapy, the emotional functioning of patients and their mothers improved [16,17].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study

Pawlowska,

Dobrowolska,

Moppert

et al. 2023

JCM

View full text Add to dashboard Cite

The aim of the study was to analyze the effectiveness and safety of anti-HCV treatment based on a pangenotypic direct-acting antiviral (DAA) regimen with glecaprevir/pibrentasvir (GLE/PIB) in children. The multi-center study was conducted in HCV-infected children who were treated in the period from November 2022 to January 2023. The analysis included 23 pediatric patients with a mean (SD) age of 9.61 (3.68) years. The cohort included 13 girls and 10 boys. The most common HCV genotypes were GT1b (n = 9, 39.1%), GT1a (n = 6, 26.1%) and GT3 (n = 5, 21.7%). The SVR was assessed at 12 weeks after the end of treatment and was 100% for both girls and boys. The conducted study showed a very good tolerance of the treatment in the entire analyzed group and confirmed a very high efficacy and safety for 8-week treatment with GLE/PIB in children over three years of age. It seems that our study is the first on the real-world use of an 8-week GLE/PIB pangenotypic therapy in a group of children aged 3–12 years and the first in Europe for adolescents aged 12–17.

show abstract

“…No SAE or early discontinuation of therapy were observed. After DAA therapy, the emotional functioning of patients and their mothers improved [16,17].…”

Section: Discussionmentioning

confidence: 99%

“…Twenty-five patients infected with HCV genotypes 1b, 2a, 2b and 2b/1b, including 15 girls and 10 boys, were enrolled in the multicenter study. The median age was 13 years (range [12][13][14][15][16][17]. A total of 12/25 (96%) adolescents achieved SVR.…”

Section: Discussionmentioning

confidence: 99%